FURLAN, ROBERTO
 Distribuzione geografica
Continente #
NA - Nord America 8.321
EU - Europa 7.486
AS - Asia 6.864
SA - Sud America 1.442
Continente sconosciuto - Info sul continente non disponibili 510
AF - Africa 134
OC - Oceania 4
Totale 24.761
Nazione #
US - Stati Uniti d'America 7.824
RU - Federazione Russa 4.364
SG - Singapore 2.492
CN - Cina 2.146
IT - Italia 1.343
BR - Brasile 1.207
HK - Hong Kong 861
VN - Vietnam 538
SE - Svezia 457
FR - Francia 361
BD - Bangladesh 333
DE - Germania 252
CA - Canada 246
GB - Regno Unito 201
IN - India 134
FI - Finlandia 92
MX - Messico 86
AR - Argentina 85
NL - Olanda 85
AT - Austria 66
PL - Polonia 64
ZA - Sudafrica 54
ES - Italia 46
EC - Ecuador 45
JP - Giappone 43
IE - Irlanda 42
TR - Turchia 42
ID - Indonesia 41
IQ - Iraq 34
CR - Costa Rica 32
JM - Giamaica 30
VE - Venezuela 29
UA - Ucraina 24
CO - Colombia 22
PK - Pakistan 22
SA - Arabia Saudita 22
RO - Romania 20
UZ - Uzbekistan 19
TT - Trinidad e Tobago 18
MA - Marocco 17
PY - Paraguay 17
MY - Malesia 15
NI - Nicaragua 15
LT - Lituania 14
TN - Tunisia 14
UY - Uruguay 14
GT - Guatemala 13
HN - Honduras 13
IR - Iran 12
NP - Nepal 12
EG - Egitto 11
KE - Kenya 11
OM - Oman 10
AE - Emirati Arabi Uniti 9
AZ - Azerbaigian 9
CL - Cile 9
KR - Corea 9
SN - Senegal 9
IL - Israele 8
LB - Libano 8
SV - El Salvador 8
AL - Albania 7
BE - Belgio 7
DZ - Algeria 7
MD - Moldavia 7
TH - Thailandia 7
BO - Bolivia 6
BS - Bahamas 6
JO - Giordania 6
PR - Porto Rico 6
CH - Svizzera 5
CW - ???statistics.table.value.countryCode.CW??? 5
DO - Repubblica Dominicana 5
PE - Perù 5
AU - Australia 4
BB - Barbados 4
BY - Bielorussia 4
KZ - Kazakistan 4
BH - Bahrain 3
CY - Cipro 3
CZ - Repubblica Ceca 3
EE - Estonia 3
GD - Grenada 3
GY - Guiana 3
HT - Haiti 3
KG - Kirghizistan 3
LY - Libia 3
NO - Norvegia 3
PA - Panama 3
PH - Filippine 3
PS - Palestinian Territory 3
SY - Repubblica araba siriana 3
ET - Etiopia 2
GA - Gabon 2
GE - Georgia 2
GP - Guadalupe 2
GR - Grecia 2
HU - Ungheria 2
KW - Kuwait 2
PT - Portogallo 2
Totale 24.232
Città #
Ashburn 1.242
Singapore 1.128
San Jose 1.045
Moscow 922
Dallas 917
Hong Kong 846
Council Bluffs 423
Milan 402
Shanghai 360
Hefei 313
Lauterbourg 291
Beijing 256
New York 221
Los Angeles 213
Ho Chi Minh City 190
Lawrence 174
Princeton 172
Phoenix 169
Santa Clara 166
São Paulo 141
Hanoi 115
Rome 102
Nuremberg 75
Orem 65
Washington 65
North Bergen 63
Atlanta 61
Miano 61
Boardman 58
Warsaw 58
Brooklyn 56
Munich 56
Montreal 55
Helsinki 53
Chennai 51
Chicago 49
Denver 45
Naples 44
London 43
Toronto 41
Houston 40
Manchester 38
Carrboro 37
Dublin 37
Stockholm 34
Amsterdam 33
Rio de Janeiro 33
Seattle 32
Tokyo 32
Da Nang 30
Guangzhou 30
Mexico City 30
Poplar 30
Turku 29
Johannesburg 28
Omaha 27
Belo Horizonte 26
Haiphong 25
Buffalo 24
San Francisco 24
San José 24
Vienna 23
Boston 22
Charlotte 22
Frankfurt am Main 22
The Dalles 22
Philadelphia 20
Miami 18
Dhaka 17
Florence 17
Kingston 17
Querétaro 17
Quito 17
Bologna 16
Brescia 16
Cesano Boscone 16
Hangzhou 16
Tashkent 16
Brasília 15
Curitiba 15
Jacksonville 15
Managua 15
Porto Alegre 15
Shenzhen 15
Turin 15
Ankara 14
Falkenstein 14
Campinas 13
Mumbai 13
Salvador 13
Calgary 12
Columbus 12
Guarulhos 12
Jeddah 12
Las Vegas 12
Modena 12
Montevideo 12
Baghdad 11
Xi'an 11
Catania 10
Totale 12.052
Nome #
Fatigue in Multiple Sclerosis Is Associated with Reduced Expression of Interleukin-10 and Worse Prospective Disease Activity 208
Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study 192
A peripheral inflammatory signature discriminates bipolar from unipolar depression: A machine learning approach 190
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicantre study 185
The unfolded protein response in amyotrophic later sclerosis: Results of a phase 2 trial 181
Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors 175
Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up 173
Brain correlates of depression, post-traumatic distress, and inflammatory biomarkers in COVID-19 survivors: A multimodal magnetic resonance imaging study 169
Low-dose interleukin 2 antidepressant potentiation in unipolar and bipolar depression: Safety, efficacy, and immunological biomarkers 151
Clinical Features and Biomarkers to Differentiate Primary and Amyotrophic Lateral Sclerosis in Patients With an Upper Motor Neuron Syndrome 147
One-year mental health outcomes in a cohort of COVID-19 survivors 143
Higher baseline interleukin-1β and TNF-α hamper antidepressant response in major depressive disorder 136
Neurofilaments light: Possible biomarker of brain modifications in bipolar disorder 132
The BDNF Val66Met Polymorphism (rs6265) Modulates Inflammation and Neurodegeneration in the Early Phases of Multiple Sclerosis 131
Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis 127
A gene therapy approach to treat demyelinating diseases using nonreplicative herpetic vectors engineered to produce cytokines 125
Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients 124
COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: A 2-year study 124
Polarized cells display asymmetric release of extracellular vesicles 122
Neuroinflammation in Bipolar Depression 122
The microrna let-7b-5p is negatively associated with inflammation and disease severity in multiple sclerosis 121
A model of HTLV-I infection in the SCID mouse 118
Mood-congruent negative thinking styles and cognitive vulnerability in depressed COVID-19 survivors: A comparison with major depressive disorder 118
Classical and unconventional pathways of vesicular release in microglia 117
Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis 117
Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients 117
Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. 116
A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis 113
Absence of central nervous system pathology in severe combined immunodeficiency mice intraperitoneally injected with peripheral blood lymphocytes from multiple sclerosis patients 113
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis 112
Lower levels of glutathione in the anterior cingulate cortex associate with depressive symptoms and white matter hyperintensities in COVID-19 survivors 112
INCREASE OF MYELOID MICROVESICLES IN THE CEREBROSPINAL FLUID AS BIOMARKER OF MICROGLIA/MACROPHAGE ACTIVATION IN NEUROLOGICAL DISORDERS 111
CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study 111
Inflammatory Markers Predict Blood Neurofilament Light Chain Levels in Acute COVID-19 Patients 110
Intranasal Administration of Extracellular Vesicles Derived from Adipose Mesenchymal Stem Cells Has Therapeutic Effect in Experimental Autoimmune Encephalomyelitis 110
Allogeneic haematopoietic stem cell transplantation in refractory neuromyelitis optica spectrum disorders 110
Neutrophil-to-lymphocyte ratio: a marker of neuro-inflammation in multiple sclerosis? 110
Absence of an intrathecal immune reaction to a helper-dependent adenoviral vector delivered into the cerebrospinal fluid of non-human primates 107
A helper dependent adenovirus efficiently delivers bioactive FGF-II to the CNS 106
MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study 106
B cell depletion attenuates CD27 signaling of T helper cells in multiple sclerosis 105
In vivo fate analysis reveals the multipotent and self-renewal features of embryonic AspM expressing cells 105
miR-21 sustains CD28 signalling and low-affinity T-cell responses at the expense of self-tolerance 105
Activation of invariant NKT cells by alpha GalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma 104
Gene and stem cell therapy for autoimmune demyelination 104
Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes 103
CSF extracellular vesicles and risk of disease activity after a first demyelinating event 103
Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis 102
iAstrocytes do not restrain T cell proliferation in vitro 100
Plasma neurofilament light chain levels and cognitive testing as predictors of fast progression in Alzheimer’s disease 100
Absence of oligoclonally restricted immunoglobulins in tears from multiple sclerosis patients 99
Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes. 99
The impact of storage on extracellular vesicles: A systematic study 98
A single nucleotide ADA genetic variant is associated to central inflammation and clinical presentation in MS: Implications for cladribine treatment 98
A machine learning approach on whole blood immunomarkers to identify an inflammation-associated psychosis onset subgroup 98
Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients 98
2D immunomic approach for the study of IgG autoantibodies in the experimental model of multiple sclerosis 98
Circulating cytotoxic immune cell composition, activation status and toxins expression associate with white matter microstructure in bipolar disorder 97
Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: role of depression and impact on quality of life 97
MiR-142-3p regulates synaptopathy-driven disease progression in multiple sclerosis 96
Extracellular Vesicles in Neuroinflammation 96
Activated macrophages release microvesicles containing polarized M1 or M2 mRNAs 96
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects 95
Acid sphingomyelinase activity triggers microparticle release from glial cells 95
Abnormal activity of the Na/Ca exchanger enhances glutamate transmission in experimental autoimmune encephalomyelitis 95
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking 94
Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysis 94
Dysregulation of MS risk genes and pathways at distinct stages of disease 93
Absence of immunoglobulin restriction in tears from multiple sclerosis patients 92
Adenovirus-mediated IL-4 transfer is protective in ischemia/reperfusion brain injury 92
Administration of an MCP-1 variant to EAE mice prevents inflammatory cell recruitment and protects from demyelination and axonal loss 92
Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-Cd20 Monoclonal Antibodies for Multiple Sclerosis Treatment 92
Changes in circulating pro-inflammatory lymphocytes and cortical excitability with extended-interval natalizumab dosing in multiple sclerosis 91
AMBRA1 Controls Regulatory T-Cell Differentiation and Homeostasis Upstream of the FOXO3-FOXP3 Axis 91
PD-1/PD-L Axis in Neuroinflammation: New Insights 90
Extracellular vesicles from adipose mesenchymal stem cells target inflamed lymph nodes in experimental autoimmune encephalomyelitis 89
Ventilation With Argon Improves Survival With Good Neurological Recovery After Prolonged Untreated Cardiac Arrest in Pigs 89
Indoleamine 2,3-Dioxygenase Deletion to Modulate Kynurenine Pathway and to Prevent Brain Injury after Cardiac Arrest in Mice 88
Cerebrospinal fluid analysis in immunoglobulin G4-related hypertrophic pachymeningitis 88
Inflammatory signature in amyotrophic lateral sclerosis predicting disease progression 88
Preventive exercise attenuates IL-2-driven mood disorders in multiple sclerosis 87
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis 87
Classification of Psychoses Based on Immunological Features: A Machine Learning Study in a Large Cohort of First-Episode and Chronic Patients 87
Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course 87
Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis 87
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome 86
Allogeneic Hematopoietic Stem Cell Transplantation For Severe Neuromyelitis Optica 86
Microbiota-produced immune regulatory bile acid metabolites control central nervous system autoimmunity 85
Mir106b-25 and Mir17-92 Are Crucially Involved in the Development of Experimental Neuroinflammation 85
Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab 84
Association between inflammation and brain microstructure in First Episode Psychosis investigated with DTI 84
PD-L2 identifies a novel subpopulation of neutrophils displaying immunoregulatory features in Multiple Sclerosis 84
Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach 84
Administration of a monomeric CCL2 variant to EAE mice inhibits inflammatory cell recruitment and protects from demyelination and axonal loss 84
Distinct protein expression networks are activated in microglia cells after stimulation with ifn and il-4 83
Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression 82
MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis 81
Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients 81
ACID SPHINGOMYELINASE TRIGGERS P2X7-INDUCED MICROPARTICLE RELEASE FROM GLIAL CELLS 81
Platelet glutamate uptake and Th1 cells inversely correlate in relapsing/remitting and in progressive multiple sclerosis 81
Totale 10.847
Categoria #
all - tutte 137.326
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 137.326


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022151 0 0 0 57 14 18 16 5 7 15 7 12
2022/20231.070 398 175 50 6 8 85 37 49 28 24 201 9
2023/2024784 7 44 108 61 103 174 20 62 8 26 34 137
2024/20253.776 376 68 54 94 130 313 499 323 662 576 324 357
2025/202614.700 1.036 1.052 1.091 1.911 1.048 399 1.486 1.110 3.876 735 446 510
2026/20274.185 523 1.124 947 1.591 0 0 0 0 0 0 0 0
Totale 24.761